MIT researchers have innovated a rapid and precise CRISPR genome-editing technique to create specific cancer-related mutations in mouse models, which could greatly enhance drug development and our understanding of tumor progression. This new method allows for the engineering of multiple mutations in the cancer-promoting Kras gene across various organs, significantly expediting the process compared to traditional approaches that take years for a single mutation. The team asserts this technique can be applied to any cancer mutation, facilitating the identification and testing of targeted therapies.
Historically, generating mouse models has been laborious and time-consuming, often requiring extensive time to analyze single mutations. By utilizing prime editing—a refined CRISPR approach that reduces errors and allows for precise genetic alterations—the researchers achieved various Kras mutations connected to lung cancer, revealing distinct tumor characteristics according to the specific mutation. The potential for this tool extends to creating models with mutations linked to resistance against current cancer treatments, opening avenues for targeted drug development. The engineered mouse models, available through a repository, are expected to encourage further research into the complex landscape of cancer mutations.
